-
公开(公告)号:US5888536A
公开(公告)日:1999-03-30
申请号:US817433
申请日:1997-08-05
申请人: Michael Mezei , Jozsef Gaal , Gabor Szekacs , Gyula Szebeni , Katalin Marmarosi , Kalman Magyar , Jozsef Lengyel , Istvan Szatmari , Agnes Turi
发明人: Michael Mezei , Jozsef Gaal , Gabor Szekacs , Gyula Szebeni , Katalin Marmarosi , Kalman Magyar , Jozsef Lengyel , Istvan Szatmari , Agnes Turi
IPC分类号: A61K9/127 , A61K31/135 , A61K31/137 , A61K47/42 , A61P25/00 , A61P25/28 , A61K31/13
CPC分类号: A61K31/137 , A61K9/127
摘要: This invention provides liposomic composition, containing as active ingredient (-)-N-.alpha.-dimethyl-N-(2-propynylphenylethylamine) (selegilin) and/or salt thereof. This composition contains: 0.1-40% by weight of selegilin and/or a salt thereof, 2 to 40% by weight of lipids, preferably phospholipids, 0 to 10% by weight of cholesterol, 0 to 20% by weight of an alcohol, 0 to 25% by weight of a glycol, 0 to 3% by weight of an antioxidant, 0 to 3% by weight of a preserving agent, 0 to 2% by weight of a viscosity influencing agent, 0 to 50% by weight of cyclodextrin or a cyclodextrin derivative and 30 to 90% by weight of water. This invention relates to pharmaceutical composition, containing the liposomic composition described and if desired, usual filling and diluting agents and other auxiliaries, preferably in oral, parenteral or transdermal form. This invention provides the process for the preparation of liposomic compositions containing selegilin and/or salt thereof. Accordingly liposomic composition of this invention may be administered for the treatment of Alzheimeir's disease, Parkinson's disease, depression, stroke, motion sickness or myelitis.
摘要翻译: PCT No.PCT / HU95 / 00052 Sec。 371日期:1997年8月5日 102(e)日期1997年8月5日PCT 1995年10月20日PCT PCT。 第WO96 / 12472号公报 日期:1996年5月2日本发明提供含有作为( - ) - N-α-二甲基-N-(2-丙炔基苯乙胺)(selegilin)和/或其盐的活性成分的脂质体组合物。 该组合物含有:0.1-40重量%的赛莱格林和/或其盐,2〜40重量%的脂质,优选磷脂,0〜10重量%的胆固醇,0〜20重量%的醇, 0〜25重量%的二醇,0〜3重量%的抗氧化剂,0〜3重量%的防腐剂,0〜2重量%的粘度影响剂,0〜50重量% 环糊精或环糊精衍生物和30〜90重量%的水。 本发明涉及包含所述脂质体组合物和如果需要的通常的填充和稀释剂和其它助剂的药物组合物,优选口服,肠胃外或透皮形式。 本发明提供了制备含有塞来昔林和/或其盐的脂质体组合物的方法。 因此,本发明的脂质体组合物可以用于治疗阿尔茨海默病,帕金森病,抑郁症,中风,运动病或脊髓炎。